Cancer

Feb 19, 2020

Cardiovascular diseases (CVDs) are one of the leading causes of death and health loss in people in the US. As per a study by the National Vital Statistics Report, every 37 seconds, one person dies of Cardiovascular diseases in the US.  Cardiovascular diseases also known as heart disease, encompasses a wide range...

Oct 10, 2019

The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insuffi...

Oct 03, 2019

Roche’s Genentech has presented positive Phase III results from the IMvigor130 study aimed at studying Tecentriq (atezolizumab) tested in combination with platinum-based chemotherapy. The drug, Tecentriq, combined with Pt-based chemotherapy showed a noteworthy improvement in patients with untreated advanced bla...

Aug 29, 2019

FDA urges Pharma giants to increase their inclusion of men in new Breast Cancer trials The recent FDA recommendations have urged the Pharma companies for the inclusion of men in the clinical trials to test new breast cancer drugs. Men rarely develop Breast cancer. Less than 1% of men develop Breast cancer. And 1...

Aug 20, 2019

Juvenescence closes a USD 100 Million Series B round Juvenescence, a life sciences company focused on treating ageing problems, has successfully raised USD 100 Million in a Series B round. The investors who took part in the funding were Grok Ventures, the investment company of Mike Cannon-Brookes (Atlassian co-...

Aug 01, 2019

Bayer and Orion's Nubeqa gets FDA recommendations for Prostate Cancer The U.S. FDA has given its nod to Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nubeqa is a steroidal androgen receptor inhibitor (ARi), and its recommendation came afte...

Jul 25, 2019

FDA Approves Eli Lilly's Baqsimi, the first treatment for Severe Hypoglycemia The U.S. FDA gave its approval to Baqsimi nasal powder, for the treatment of Severe Hypoglycaemia in patients with diabetes ages four and older. Baqsimi is a powder administered into the nose and is the first non-injectable emergency t...

Jun 20, 2019

Gilead jumps into a competitive Protein degradation field, signs a USD 45 M Nurix deal Gilead Sciences is turning to Nurix Therapeutics for enhancing cancer pipeline. Gilead is ready to pay USD 45 million upfront, and if all the targets are achieved the deal could reach up to USD 2.3 billion. Nurix is a drug de...

Jun 08, 2019

World Brain Tumor Day World Brain Tumor Day is focussed at raising awareness about brain tumor and educating people about cancer which is not very common. Every year, June 8 is seen as World Brain Tumor Day. The day is also meant for those who are suffering from a brain tumor and help them deal with the condi...

Jun 06, 2019

Cancer biotech Inhibrx files for USD 75 M IPO Celgene-partnered biotech Inhibrx aftersecuring USD 40 Million from Viking Global Investors, has filed for USD 75 million IPO. Built on a single-domain antibody platform, it has three oncology programs in human clinical trials, a rare disease program, and two preclin...